@prefix rr:    <http://www.w3.org/ns/r2rml#> .
@prefix ont:   <http://ontologies.vub.be/oecd#> .
@prefix rdf:   <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd:   <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs:  <http://www.w3.org/2000/01/rdf-schema#> .

<http://toxin.vub.be/resource/test/repeated-dose-toxicity/oecd_412/3>
        a       ont:Test .

<http://toxin.vub.be/resource/test/repeated-dose-toxicity/oecd_412/6>
        a       ont:Test .

<http://toxin.vub.be/resource/test/repeated-dose-toxicity/oecd_412/1>
        a                               ont:Test ;
        ont:compound                    <http://toxin.vub.be/resource/compound/Phenoxyethanol> ;
        ont:compoundLabel               "Phenoxyethanol" ;
        ont:endpoints_conclusion        "the no-observed-adverse-effect concentration (noaec) for local effects in upper airways and lung was determined to be 48.2 mg/m3\r\n." ;
        ont:endpoints_description_of_pod
                "noaec mg/m3" ;
        ont:endpoints_discussion_and_results
                "repeated inhalation exposure of rats to an aerosol coNTAining up to 1000 mg/m³ of 2- Phenoxyethanol for 6 hours per day for a total of 10 exposure days showed low inhalation toxicity. there were no treatment-related changes in clinical chemistry or haematology and no treatment related histopathological changes indicative of systemic toxicity" ;
        ont:endpoints_gross_pathology_larynx
                "as minimal to slight degeneration/squamous metaplasia, hyperplasia/hypertrophy and minimal to slight inflammatory cell infiltrates were noted, indicating irritation potential in larynx in mid- and high-dose animals." ;
        ont:endpoints_gross_pathology_lungs
                "as minimal to slight degeneration/squamous metaplasia, hyperplasia/hypertrophy and\r\nminimal to slight inflammatory cell infiltrates were noted, indicating irritation potential in\r\nthe lung in mid- and high-dose animals." ;
        ont:endpoints_gross_pathology_nasopharyngeal_tissues
                "as minimal to slight degeneration/squamous metaplasia, hyperplasia/hypertrophy and\r\nminimal to slight inflammatory cell infiltrates were noted, indicating irritation potential in\r\nthe nasal cavity in mid- and high-dose animals." ;
        ont:endpoints_moribund_or_dead_animals_prior_to_study_termination
                "no" ;
        ont:endpoints_observations_body_weight
                "decreased body weight gain (females only)" ;
        ont:endpoints_observations_clinical_observation_changes_in_somatomotor_activity_and_behaviour_patterns
                "34.4" ;
        ont:endpoints_observations_clinical_observation_changes_in_the_circulatory_system
                "on exposure days, the clinical examination was performed before, during and after exposure. body weight and food consumption were determined at the start of the exposure period, on day 7 and on day 13. at study termination, clinical-pathological examinations of the blood, gross necropsy, measurement of organ weights and histopathological examinations of selected organs were conducted (liver, kidneys, adrenals, testes, thymus, spleen, lung).low inhalation toxicity, decreased body weight gain (females only) and food consumption (males and females) were observed in animals exposed to 1000 mg/m³ of 2-Phenoxyethanol. there were no treatment-related changes in clinical chemistry or haematology and no treatment related histopathological changes indicative of systemic toxicity. morphological changes such as minimal to slight degeneration/squamous metaplasia, hyperplasia/hypertrophy and minimal to slight inflammatory cell infiltrates were noted, indicating irritation potential in the nasal cavity, larynx and lung in mid- and high-dose animals. lung weights were increased in mid- and high-dose males. " ;
        ont:endpoints_observations_clinical_observation_changes_in_the_nervous_system
                "decreased body weight gain and food consumption" ;
        ont:endpoints_observations_clinical_observation_convulsions
                "nasal cavity, larynx and lung " ;
        ont:endpoints_observations_clinical_observation_diarrhoea
                "no" ;
        ont:endpoints_observations_clinical_observation_sleep
                "the noaec for local effects in upper airways and lung was determined to be 48.2mg/m3/day" ;
        ont:endpoints_observations_clinical_observation_tremors
                "noaec  mg/m3/day" ;
        ont:endpoints_observations_food_and_water_consumption
                "decreased food consumption (males and females)" ;
        ont:endpoints_observations_organ_weight_and_organbody_weight
                "lung weights were increased in mid- and high-dose males." ;
        ont:endpoints_point_of_departure_noael
                "48.2" ;
        ont:guideline                   <http://toxin.vub.be/resource/guideline/OECD%20412> ;
        ont:guidelineLabel              "OECD 412" ;
        ont:pdf_link                    "https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/SCCS_o_195.pdf" ;
        ont:reliability_control_group   "a concurrent control group was exposed to conditioned air" ;
        ont:reliability_glp             "yes" ;
        ont:reliability_klimisch_score  "2" ;
        ont:reliability_ref_in_dossier  "3" ;
        ont:reliability_sccs_comment_to_test
                "no data on lung lavage is available. the noaec derived should be multiplied with a factor of 5/7 in order to take into account the intermittent exposure (5 days a week). an adjusted noaec of 34.4 mg/m3/day may be used." ;
        ont:reliability_year            "2007" ;
        ont:test_method__test_condition_analytical_concentrations
                "0, 48.2, 246, 1070" ;
        ont:test_method__test_condition_dose_level_unit
                "mg/m3" ;
        ont:test_method__test_condition_duration_of_exposure
                "14 d" ;
        ont:test_method__test_condition_inhalation_exposure_duration_of_exposure
                "6" ;
        ont:test_method__test_condition_inhalation_exposure_inhalation_chamber_noseonly
                "nose/head only" ;
        ont:test_method__test_condition_nominal_concentrations
                "0, 40, 200, 1000" ;
        ont:test_method__test_condition_repeated_administration_scheme
                "5 days/week" ;
        ont:test_method__test_condition_test_animal_n_animals__group
                "10" ;
        ont:test_method__test_condition_test_animal_sex
                "f & m" ;
        ont:test_method__test_condition_test_animal_speciesstrain
                "rat/wistar" ;
        ont:test_method_test_substance_chemical_batch_nr
                "41183068" ;
        ont:test_method_test_substance_physical_form
                "liquid aerosol" ;
        ont:test_method_test_substance_purity
                "> 99.9" ;
        ont:test_method_test_substance_vehicle_name
                "air" ;
        ont:type                        "in vivo" .

<http://toxin.vub.be/resource/compound/Phenoxyethanol>
        a               ont:Compound ;
        rdfs:label      "Phenoxyethanol" ;
        ont:compoundOf  <http://toxin.vub.be/resource/dossier/Phenoxyethanol> .

<http://toxin.vub.be/resource/dossier/Decamethylcyclopentasiloxane%20%28cyclopentasiloxane%2C%20D5%29>
        a             ont:Report ;
        rdfs:label    "Decamethylcyclopentasiloxane (cyclopentasiloxane, D5)" ;
        rdfs:seeAlso  <https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/SCCS_o_174.pdf> ;
        ont:contains  <http://toxin.vub.be/resource/test/repeated-dose-toxicity/oecd_412/2> .

<http://toxin.vub.be/resource/test/repeated-dose-toxicity/oecd_412/4>
        a       ont:Test .

<http://toxin.vub.be/resource/compound/Decamethylcyclopentasiloxane%20%28cyclopentasiloxane%2C%20D5%29>
        a               ont:Compound ;
        rdfs:label      "Decamethylcyclopentasiloxane (cyclopentasiloxane, D5)" ;
        ont:compoundOf  <http://toxin.vub.be/resource/dossier/Decamethylcyclopentasiloxane%20%28cyclopentasiloxane%2C%20D5%29> .

<http://toxin.vub.be/resource/test/repeated-dose-toxicity/oecd_412/2>
        a                               ont:Test ;
        ont:additional_information      "SCCS conclusion on general toxicity: the SCCS has identified the liver as a potential target organ following repeated-dose oral exposure and liver, lungs and uterus as potential target organs following repeated-dose inhalation exposure. the effects observed on the liver were mainly an increase in liver weight. in the subchronic oral study (ref 45), this increase in liver weight was not accompanied by histopathological lesions and no biologically relevant alterations in enzymatic activities were observed. no liver effects were reported in the chronic inhalation toxicity/carcinogenicity study. therefore, the SCCS followed the hed guidance document on how to interpret hepatocellular hypertrophy (2002) and concluded that these liver effects are not adverse. therefore the oral dose of 100 mg/kg bw may be considered as a NOAEL. concerning exposure to d5 by inhalation, the inhaled concentration of 49 ppm was considered as a noaec." ;
        ont:compound                    <http://toxin.vub.be/resource/compound/Decamethylcyclopentasiloxane%20%28cyclopentasiloxane%2C%20D5%29> ;
        ont:compoundLabel               "Decamethylcyclopentasiloxane (cyclopentasiloxane, D5)" ;
        ont:endpoints_clinical_pathology_haematology_mean_corpuscular_haemoglobin_concentration
                "in rats exposed to 1.5 and 2.29 mg/L (96 and 151/197 ppm) there was slightly decreased mean corpuscular haemoglobin concentration. there was no apparent relationship between these effects and the treatment." ;
        ont:endpoints_clinical_pathology_haematology_mean_corpuscular_volume
                "in rats exposed to 1.5 and 2.29 mg/L (96 and 151/197 ppm) there was a slightly increased mean corpuscular volume. there was no apparent relationship between these effects and the treatment." ;
        ont:endpoints_clinical_pathology_haematology_total_leucocyte_count
                "in rats exposed to 1.5 and 2.29 mg/L (96 and 151/197 ppm) there was a  slightly increased leukocyte and lymphocyte counts in males. there was no apparent relationship between these effects and the treatment." ;
        ont:endpoints_conclusion        "results indicate repeated inhalation exposure to d5 induced an early non-sustained increase in liver weight and an early burst of hepatocellular hyperplasia and centrilobular hypertrophy in female rats exposed to concentrations of 160 ppm." ;
        ont:endpoints_gross_pathology_liver
                "an increase (>10%) in absolute and relative liver weight with slight hepatocellular hypertrophy (females only) were observed at the highest exposure concentration of 2.29/3.71 mg d5/L. i.e. 151/197 ppm." ;
        ont:endpoints_gross_pathology_lungs
                "minimal to slight interstitial inflammation in the lungs (males and females) was observed at the highest exposure concentration of 2.29/3.71 mg d5/L. i.e. 151/197 ppm." ;
        ont:endpoints_gross_pathology_olfactory_bulb
                "increased incidence of goblet cell proliferation in the nasal cavity (males and females), was observed at the highest exposure concentration of 2.29/3.71 mg d5/L. i.e. 151/197 ppm. " ;
        ont:endpoints_observations_clinical_observation_changes_in_skin
                "no behavioural abnormalities or mortalities were seen during the study. no effects were seen on mortality, body weight or body weight gain, food iNTAke, or clinical signs. urinalysis and biochemistry data indicated no changes of toxicological significance at termination of the treatment. however, a few minor changes with statistical significance were recorded in rats exposed to 1.5 and 2.29 mg/L (96 and 151/197 ppm). an increase (>10%) in absolute and relative liver weight with slight hepatocellular hypertrophy (females only), increased incidence of goblet cell proliferation in the nasal cavity (males and females), and minimal to slight interstitial inflammation in the lungs (males and females) were observed at the highest exposure concentration of 2.29/3.71 mg d5/L. i.e. 151/197 ppm. " ;
        ont:endpoints_observations_organ_weight_and_organbody_weight
                "in rats exposed to 1.5 and 2.29 mg/L (96 and 151/197 ppm). an increase (>10%) in absolute and relative liver weight with slight hepatocellular hypertrophy (females only).  mean lung absolute weights and lung to brain weight ratios were significantly increased (<10%) in males and females at the highest dose." ;
        ont:pdf_link                    "https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/SCCS_o_174.pdf" ;
        ont:reliability_ref_in_dossier  "38" ;
        ont:test_method__test_condition_dose_level_unit
                "mg /l (0, 28, 42, 96, 151/197 ppm)" ;
        ont:test_method__test_condition_duration_of_exposure
                "28 days" ;
        ont:test_method__test_condition_inhalation_exposure_duration_of_exposure
                "6" ;
        ont:test_method__test_condition_inhalation_exposure_inhalation_chamber_noseonly
                "nose only" ;
        ont:test_method__test_condition_nominal_concentrations
                "0, 0.45, 0.66, 1.34, 2.29/3.71 " ;
        ont:test_method__test_condition_repeated_administration_scheme
                "5 days/week for 4 weeks. animals were exposed to the highest exposure concentration of 2.29 mg/l (151 ppm) for days 1 to 6 while the exposure to 3.71 mg/l (197 ppm) was for the remaining duration of the study (week 2 to 4)." ;
        ont:test_method__test_condition_test_animal_n_animals__group
                "10" ;
        ont:test_method__test_condition_test_animal_sex
                "f & m" ;
        ont:test_method__test_condition_test_animal_speciesstrain
                "rat/fischer 344" ;
        ont:test_method_test_substance_additional_info
                "test substance: d5" ;
        ont:test_method_test_substance_homogeneity_and_stability
                "according to physicochemical specifications, 160 ppm is the highest D5 exposure concentration that can be reliably generated and maintained as a vapor without interference by aerosol formation" ;
        ont:test_method_test_substance_physical_form
                "vapor" ;
        ont:type                        "in vivo" .

<http://toxin.vub.be/resource/test/repeated-dose-toxicity/oecd_412/7>
        a             ont:Test ;
        ont:pdf_link  "52" .

<http://toxin.vub.be/resource/dossier/Phenoxyethanol>
        a              ont:Report ;
        rdfs:label     "Phenoxyethanol" ;
        rdfs:seeAlso   <https://ec.europa.eu/health/scientific_committees/consumer_safety/docs/SCCS_o_195.pdf> ;
        ont:contains   <http://toxin.vub.be/resource/test/repeated-dose-toxicity/oecd_412/1> ;
        ont:guideline  <http://toxin.vub.be/resource/guideline/OECD%20412> .

<http://toxin.vub.be/resource/test/repeated-dose-toxicity/oecd_412/5>
        a       ont:Test .
